Skip to main content
Top
Published in: Psychiatric Quarterly 2/2012

01-06-2012 | Original Paper

Is There Evidence for Late Cognitive Decline in Chronic Schizophrenia?

Authors: Jharna N. Shah, Salah U. Qureshi, Ali Jawaid, Paul E. Schulz

Published in: Psychiatric Quarterly | Issue 2/2012

Login to get access

Abstract

Schizophrenia (SZP) has been historically referred to as “dementia praecox” because of the recognition that its onset is associated with deficits in memory, attention and visuospatial orientation. We wondered whether there is evidence for additional cognitive decline late in the course of chronic SZP. This review examined the evidence (1) for cognitive decline late in the course of chronic SZP, (2) for how often the late cognitive decline occurs, and (3) whether the cognitive decline in late-life SZP is related to pathophysiology of SZP versus the superimposition of another type of dementia. A PUBMED search was performed combining the MESH terms schizophrenia and dementia, cognitive decline, cognitive impairment and cognitive deficits. A manual search of article bibliographies was also performed. We included longitudinal clinical studies employing standard tests of cognition. Cross-sectional studies and those that did not test cognition through standard cognitive tests were excluded. The initial search produced 3898 studies. Employing selection criteria yielded twenty-three studies. Our data extraction tool included the number of patients in the study, whether a control group was present, the age of patients at baseline and follow-up, the study setting (inpatients versus outpatients), the cognitive tests employed, study duration, and results. Only three longitudinal studies tested for dementia using Diagnostic and statistical manual of mental disorder (DSM) or International classification of disease (ICD) criteria and compared them to controls: two studies demonstrated an increase in the prevalence of dementia and one did not. Twenty longitudinal studies tested for one or more cognitive domains without employing standard criteria for dementia: twelve studies demonstrated a heterogeneous pattern of cognitive decline and eight did not. Studies generally did not control for known risk factors for cognitive impairment such as education, vascular risk factors, apolipoprotein (ApoE) genotype and family history. The evidence for late cognitive decline in SZP is mixed, but, slightly more studies suggest that it occurs. If it occurs, it is unclear whether it is related to SZP or other risks for cognitive impairment. Hence, prospective, longitudinal, controlled studies are needed to confirm that there is progressive cognitive decline in chronic SZP which occurs independent of other risk factors for cognitive impairment.
Literature
1.
go back to reference Schizophrenia-U.S. Department of Health and Human Services, National Institutes of Health National Institute of Mental Health NIH Publication No. 09-3517 Revised 2009 Schizophrenia-U.S. Department of Health and Human Services, National Institutes of Health National Institute of Mental Health NIH Publication No. 09-3517 Revised 2009
2.
go back to reference Barbato A: Schizophrenia and Public health. Nations for Mental Health. WHO/MSA/NAM/97.6, 1998 Barbato A: Schizophrenia and Public health. Nations for Mental Health. WHO/MSA/NAM/97.6, 1998
3.
go back to reference Asarnow RF: Neurocognitive impairments in schizophrenia: A piece of the epigenetic puzzle. European Child & Adolescent Psychiatry 8(Suppl 1):I5–8, 1999PubMedCrossRef Asarnow RF: Neurocognitive impairments in schizophrenia: A piece of the epigenetic puzzle. European Child & Adolescent Psychiatry 8(Suppl 1):I5–8, 1999PubMedCrossRef
4.
go back to reference Ciompi L: Catamnestic long-term study on the course of life and aging of schizophrenics. Schizophrenia Bulletin 6(4):606–618, 1980PubMed Ciompi L: Catamnestic long-term study on the course of life and aging of schizophrenics. Schizophrenia Bulletin 6(4):606–618, 1980PubMed
5.
go back to reference de Vries PJ, Honer WG, Kemp PM et al.: Dementia as a complication of schizophrenia. Journal of Neurology, Neurosurgery & Psychiatry 70(5):588–596, 2001PubMedCrossRef de Vries PJ, Honer WG, Kemp PM et al.: Dementia as a complication of schizophrenia. Journal of Neurology, Neurosurgery & Psychiatry 70(5):588–596, 2001PubMedCrossRef
6.
go back to reference Banaschewski T, Schulz E, Martin M, Remschmidt H: Cognitive functions and psychopathological symptoms in early-onset schizophrenia. European Child & Adolescent Psychiatry 9(1):11–20, 2000PubMedCrossRef Banaschewski T, Schulz E, Martin M, Remschmidt H: Cognitive functions and psychopathological symptoms in early-onset schizophrenia. European Child & Adolescent Psychiatry 9(1):11–20, 2000PubMedCrossRef
7.
go back to reference Kørner A, Lopez AG, Lauritzen L et al.: Late and very-late first-contact schizophrenia and the risk of dementia—a nationwide register based study. International Journal of Geriatric Psychiatry 24:61–67, 2009PubMedCrossRef Kørner A, Lopez AG, Lauritzen L et al.: Late and very-late first-contact schizophrenia and the risk of dementia—a nationwide register based study. International Journal of Geriatric Psychiatry 24:61–67, 2009PubMedCrossRef
8.
go back to reference Brodaty H, Sachdev P, Koschera A, et al.: Long-term outcome of late-onset schizophrenia: 5-year follow-up study. The British Journal of Psychiatry 183:213–219, 2003PubMedCrossRef Brodaty H, Sachdev P, Koschera A, et al.: Long-term outcome of late-onset schizophrenia: 5-year follow-up study. The British Journal of Psychiatry 183:213–219, 2003PubMedCrossRef
9.
go back to reference Rabins PV, Lavrisha M: Long-term follow-up and phenomenologic differences distinguish among late-onset schizophrenia, late-life depression, and progressive dementia. American Journal of Geriatric Psychiatry 11:6, 2003. Rabins PV, Lavrisha M: Long-term follow-up and phenomenologic differences distinguish among late-onset schizophrenia, late-life depression, and progressive dementia. American Journal of Geriatric Psychiatry 11:6, 2003.
10.
go back to reference Goldberg TE, Hyde TM, Kleinman JE, et al.: Course of schizophrenia: neuropsychological evidence for a static encephalopathy. Schizophrenia Bulletin 19:797–804, 1993PubMed Goldberg TE, Hyde TM, Kleinman JE, et al.: Course of schizophrenia: neuropsychological evidence for a static encephalopathy. Schizophrenia Bulletin 19:797–804, 1993PubMed
11.
go back to reference Lieberman JA: Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective. Biological Psychiatry 46(6):729–739, 1999PubMedCrossRef Lieberman JA: Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective. Biological Psychiatry 46(6):729–739, 1999PubMedCrossRef
12.
go back to reference Farmer ME, Kittner SJ, Rae DS, et al.: Education and change in cognitive function. The Epidemiologic Catchment Area Study. Annals of Epidemiology 5:1–7, 1995PubMedCrossRef Farmer ME, Kittner SJ, Rae DS, et al.: Education and change in cognitive function. The Epidemiologic Catchment Area Study. Annals of Epidemiology 5:1–7, 1995PubMedCrossRef
13.
go back to reference Corral M, Rodríguez M, Amenedo E et al. Cognitive reserve, age, and neuropsychological performance in healthy participants. Developmental Neuropsychology 29(3):479–491, 2006PubMedCrossRef Corral M, Rodríguez M, Amenedo E et al. Cognitive reserve, age, and neuropsychological performance in healthy participants. Developmental Neuropsychology 29(3):479–491, 2006PubMedCrossRef
14.
go back to reference Cohn T, Prud’homme D, Streiner D et al.: Characterizing coronary heart disease risk in chronic schizophrenia: High prevalence of the metabolic syndrome. Canadian Journal of Psychiatry 49(11):753–660, 2004PubMed Cohn T, Prud’homme D, Streiner D et al.: Characterizing coronary heart disease risk in chronic schizophrenia: High prevalence of the metabolic syndrome. Canadian Journal of Psychiatry 49(11):753–660, 2004PubMed
15.
go back to reference Stahl SM, Mignon L, Meyer JM: Which comes first: Atypical antipsychotic treatment or cardioembolic risk? Acta Psychiatrica Scandinavica. 119(3):171–179, 2009PubMedCrossRef Stahl SM, Mignon L, Meyer JM: Which comes first: Atypical antipsychotic treatment or cardioembolic risk? Acta Psychiatrica Scandinavica. 119(3):171–179, 2009PubMedCrossRef
16.
go back to reference Lin HC, Hsiao FH, Pfeiffer S, et al.: An increased risk of stroke among young schizophrenia patients. Schizophrenia Research 101(1–3):234–241, 2008PubMedCrossRef Lin HC, Hsiao FH, Pfeiffer S, et al.: An increased risk of stroke among young schizophrenia patients. Schizophrenia Research 101(1–3):234–241, 2008PubMedCrossRef
17.
go back to reference Malaspina D, Goetz RR, Friedman JH, et al.: Traumatic brain injury and schizophrenia in members of schizophrenia and bipolar disorder pedigrees. The American Journal of Psychiatry 158:440–446, 2001PubMedCrossRef Malaspina D, Goetz RR, Friedman JH, et al.: Traumatic brain injury and schizophrenia in members of schizophrenia and bipolar disorder pedigrees. The American Journal of Psychiatry 158:440–446, 2001PubMedCrossRef
18.
go back to reference Dean B, Laws SM, Hone E, et al.: Increased levels of apolipoprotein E in the frontal cortex of subjects with schizophrenia. Biological Psychiatry 54(6):616–622, 2003PubMedCrossRef Dean B, Laws SM, Hone E, et al.: Increased levels of apolipoprotein E in the frontal cortex of subjects with schizophrenia. Biological Psychiatry 54(6):616–622, 2003PubMedCrossRef
19.
go back to reference Schürhoff F, Krebs MO, Szöke A, et al.: Apolipoprotein E in schizophrenia: A French association study and meta-analysis. American Journal of Medical Genetics B: Neuropsychiatric Genetics 119B (1):18–23, 2003PubMedCrossRef Schürhoff F, Krebs MO, Szöke A, et al.: Apolipoprotein E in schizophrenia: A French association study and meta-analysis. American Journal of Medical Genetics B: Neuropsychiatric Genetics 119B (1):18–23, 2003PubMedCrossRef
20.
go back to reference Hata T, Kunugi H, Nanko S, et al.: Possible effect of the APOE epsilon 4 allele on the hippocampal volume and asymmetry in schizophrenia. American Journal of Medical Genetics 114(6):641–642, 2002PubMedCrossRef Hata T, Kunugi H, Nanko S, et al.: Possible effect of the APOE epsilon 4 allele on the hippocampal volume and asymmetry in schizophrenia. American Journal of Medical Genetics 114(6):641–642, 2002PubMedCrossRef
21.
go back to reference Jeste DV, Gladsjo JA, Lindamer LA, et al.: Medical comorbidities in Schizophrenia. Schizophrenia Bulletin 22(3):413–430, 1996PubMedCrossRef Jeste DV, Gladsjo JA, Lindamer LA, et al.: Medical comorbidities in Schizophrenia. Schizophrenia Bulletin 22(3):413–430, 1996PubMedCrossRef
22.
go back to reference Niizato K, Genda K, Nakamura R, et al.: Cognitive decline in schizophrenics with AD a mini-review of neuropsychological and neuropathological studies. Progress in Neuro-Psychopharmacology & Biological Psychiatry 25:1359–1366, 2001CrossRef Niizato K, Genda K, Nakamura R, et al.: Cognitive decline in schizophrenics with AD a mini-review of neuropsychological and neuropathological studies. Progress in Neuro-Psychopharmacology & Biological Psychiatry 25:1359–1366, 2001CrossRef
23.
go back to reference Ortakov V, Mancevski B, Keilp J, et al.: Application of cognitive scales to medical records of schizophrenia inpatients. Schizophrenia Research 35(2):131–140, 1999PubMedCrossRef Ortakov V, Mancevski B, Keilp J, et al.: Application of cognitive scales to medical records of schizophrenia inpatients. Schizophrenia Research 35(2):131–140, 1999PubMedCrossRef
24.
go back to reference CERAD: CERAD 1986–1996, Documentation and Data. Archive Rev 1.0, March 1996. Durham, NC, 1996 CERAD: CERAD 1986–1996, Documentation and Data. Archive Rev 1.0, March 1996. Durham, NC, 1996
25.
go back to reference Friedman JI, Harvey PD, Coleman T, et al.: Six-year follow-up study of cognitive and functional status across the lifespan in schizophrenia: A comparison with Alzheimer’s disease and normal aging. The American Journal of Psychiatry 158(9):1441–1448, 2001PubMedCrossRef Friedman JI, Harvey PD, Coleman T, et al.: Six-year follow-up study of cognitive and functional status across the lifespan in schizophrenia: A comparison with Alzheimer’s disease and normal aging. The American Journal of Psychiatry 158(9):1441–1448, 2001PubMedCrossRef
26.
go back to reference Raven JC: Standard Progressive Matrices. London, Lewis, 1958a Raven JC: Standard Progressive Matrices. London, Lewis, 1958a
27.
go back to reference Raven JC: The Mill Hill Vocabulary Scale. London, Lewis, 1958b Raven JC: The Mill Hill Vocabulary Scale. London, Lewis, 1958b
28.
go back to reference Morrison G, O’Carroll R, McCreadie R: Long-term course of cognitive impairment in schizophrenia. The British Journal of Psychiatry 189:556–557, 2006PubMedCrossRef Morrison G, O’Carroll R, McCreadie R: Long-term course of cognitive impairment in schizophrenia. The British Journal of Psychiatry 189:556–557, 2006PubMedCrossRef
29.
go back to reference Waddington JL, Youssef HA: Cognitive dysfunction in chronic schizophrenia followed prospectively over 10 years and its longitudinal relationship to the emergence of tardive dyskinesia. Psychological Medicine 26(4):681–688, 1996PubMedCrossRef Waddington JL, Youssef HA: Cognitive dysfunction in chronic schizophrenia followed prospectively over 10 years and its longitudinal relationship to the emergence of tardive dyskinesia. Psychological Medicine 26(4):681–688, 1996PubMedCrossRef
30.
go back to reference Harvey PD, Silverman JM, Mohs RC, et al.: Cognitive decline in late-life schizophrenia: A longitudinal study of geriatric chronically hospitalized patients. Biological Psychiatry 45(1):32–40, 1999PubMedCrossRef Harvey PD, Silverman JM, Mohs RC, et al.: Cognitive decline in late-life schizophrenia: A longitudinal study of geriatric chronically hospitalized patients. Biological Psychiatry 45(1):32–40, 1999PubMedCrossRef
31.
go back to reference Harvey PD, Parrella M, White L, et al.: Convergence of cognitive and adaptive decline in late-life schizophrenia. Schizophrenia Research 35(1):77–84, 1999PubMedCrossRef Harvey PD, Parrella M, White L, et al.: Convergence of cognitive and adaptive decline in late-life schizophrenia. Schizophrenia Research 35(1):77–84, 1999PubMedCrossRef
32.
go back to reference Friedman JI, Harvey PD, McGurk SR, et al.: Correlates of change in functional status of institutionalized geriatric schizophrenic patients: Focus on medical comorbidity. The American Journal of Psychiatry 159(8):1388–1394, 2002PubMedCrossRef Friedman JI, Harvey PD, McGurk SR, et al.: Correlates of change in functional status of institutionalized geriatric schizophrenic patients: Focus on medical comorbidity. The American Journal of Psychiatry 159(8):1388–1394, 2002PubMedCrossRef
33.
go back to reference Harvey PD, Bertisch H, Friedman JI, et al.: The course of functional decline in geriatric patients with schizophrenia: Cognitive-functional and clinical symptoms as determinants of change. American Journal of Geriatric Psychiatry 11(6):610–619, 2003PubMed Harvey PD, Bertisch H, Friedman JI, et al.: The course of functional decline in geriatric patients with schizophrenia: Cognitive-functional and clinical symptoms as determinants of change. American Journal of Geriatric Psychiatry 11(6):610–619, 2003PubMed
34.
go back to reference Meagher DJ, Quinn JF, Bourke S, et al.: Longitudinal assessment of psychopathological domains over late-stage schizophrenia in relation to duration of initially untreated psychosis: 3-year prospective study in a long-term inpatient population. Psychiatry Research 126(3):217–227, 2004PubMedCrossRef Meagher DJ, Quinn JF, Bourke S, et al.: Longitudinal assessment of psychopathological domains over late-stage schizophrenia in relation to duration of initially untreated psychosis: 3-year prospective study in a long-term inpatient population. Psychiatry Research 126(3):217–227, 2004PubMedCrossRef
35.
go back to reference Chemerinski E, Reichenberg A, Kirkpatrick B, et al.: Three dimensions of clinical symptoms in elderly patients with schizophrenia: prediction of six-year cognitive and functional status. Schizophrenia Research 85(1–3):12–19, 2006PubMedCrossRef Chemerinski E, Reichenberg A, Kirkpatrick B, et al.: Three dimensions of clinical symptoms in elderly patients with schizophrenia: prediction of six-year cognitive and functional status. Schizophrenia Research 85(1–3):12–19, 2006PubMedCrossRef
36.
go back to reference White L, Friedman JI, Bowie CR, et al.: Long-term outcomes in chronically hospitalized geriatric patients with schizophrenia: Retrospective comparison of first generation and second generation antipsychotics. Schizophrenia Research 88(1–3):127–134, 2006PubMedCrossRef White L, Friedman JI, Bowie CR, et al.: Long-term outcomes in chronically hospitalized geriatric patients with schizophrenia: Retrospective comparison of first generation and second generation antipsychotics. Schizophrenia Research 88(1–3):127–134, 2006PubMedCrossRef
37.
go back to reference Nayak Savla G, Moore DJ, Roesch SC, et al.: An evaluation of longitudinal neurocognitive performance among middle-aged and older schizophrenia patients: Use of mixed-model analyses. Schizophrenia Research 83(2–3):215–223, 2006PubMedCrossRef Nayak Savla G, Moore DJ, Roesch SC, et al.: An evaluation of longitudinal neurocognitive performance among middle-aged and older schizophrenia patients: Use of mixed-model analyses. Schizophrenia Research 83(2–3):215–223, 2006PubMedCrossRef
38.
go back to reference Harvey PD, White L, Parrella M, et al.: The longitudinal stability of cognitive impairment in schizophrenia. Mini-mental state scores at one- and two-year follow-ups in geriatric in-patients. The British Journal of Psychiatry 166(5):630–633, 1995PubMedCrossRef Harvey PD, White L, Parrella M, et al.: The longitudinal stability of cognitive impairment in schizophrenia. Mini-mental state scores at one- and two-year follow-ups in geriatric in-patients. The British Journal of Psychiatry 166(5):630–633, 1995PubMedCrossRef
39.
go back to reference Harvey PD, Lombardi J, Leibman M, et al.: Cognitive impairment and negative symptoms in geriatric chronic schizophrenic patients: A follow-up study. Schizophrenia Research 22(3):223–231, 1996PubMedCrossRef Harvey PD, Lombardi J, Leibman M, et al.: Cognitive impairment and negative symptoms in geriatric chronic schizophrenic patients: A follow-up study. Schizophrenia Research 22(3):223–231, 1996PubMedCrossRef
40.
go back to reference Harvey PD, Lombardi J, Leibman M, et al.: Performance of chronic schizophrenia patients on cognitive neuropsychological measures sensitive to dementia. International Journal of Geriatric Psychiatry 11:621–627, 1996CrossRef Harvey PD, Lombardi J, Leibman M, et al.: Performance of chronic schizophrenia patients on cognitive neuropsychological measures sensitive to dementia. International Journal of Geriatric Psychiatry 11:621–627, 1996CrossRef
41.
go back to reference McGurk SR, Moriarty PJ, Harvey PD, et al.: The longitudinal relationship of clinical symptoms, cognitive functioning, and adaptive life in geriatric schizophrenia. Schizophrenia Research 42(1):47–55, 2000PubMedCrossRef McGurk SR, Moriarty PJ, Harvey PD, et al.: The longitudinal relationship of clinical symptoms, cognitive functioning, and adaptive life in geriatric schizophrenia. Schizophrenia Research 42(1):47–55, 2000PubMedCrossRef
42.
go back to reference Laks J, Fontenelle LF, Chalita A, et al.: Absence of dementia in late-onset schizophrenia: A one year follow-up of a Brazilian case series. Arq Neuropsiquiatr 64(4):946–949, 2006PubMedCrossRef Laks J, Fontenelle LF, Chalita A, et al.: Absence of dementia in late-onset schizophrenia: A one year follow-up of a Brazilian case series. Arq Neuropsiquiatr 64(4):946–949, 2006PubMedCrossRef
43.
go back to reference Heaton RK, Gladsjo JA, Palmer BW, et al.: Stability and course of neuropsychological deficits in schizophrenia. Archives of General Psychiatry 58(1):24–32, 2001PubMedCrossRef Heaton RK, Gladsjo JA, Palmer BW, et al.: Stability and course of neuropsychological deficits in schizophrenia. Archives of General Psychiatry 58(1):24–32, 2001PubMedCrossRef
44.
go back to reference Palmer BW, Bondi MW, Twamley EW, et al.: Are late-onset schizophrenia spectrum disorders neurodegenerative conditions? Annual rates of change on two dementia measures. The Journal of Neuropsychiatry and Clinical Neurosciences 15(1):45–52, 2003PubMedCrossRef Palmer BW, Bondi MW, Twamley EW, et al.: Are late-onset schizophrenia spectrum disorders neurodegenerative conditions? Annual rates of change on two dementia measures. The Journal of Neuropsychiatry and Clinical Neurosciences 15(1):45–52, 2003PubMedCrossRef
45.
go back to reference Lewis R: Should cognitive deficit be a diagnostic criterion for schizophrenia? Journal of Psychiatry & Neuroscience 29(2):102–113, 2004PubMed Lewis R: Should cognitive deficit be a diagnostic criterion for schizophrenia? Journal of Psychiatry & Neuroscience 29(2):102–113, 2004PubMed
46.
go back to reference Waddington JL, Youssef HA, Dolphin C, et al.: Cognitive dysfunction, negative symptoms and tardive dyskinesia in schizophrenia. Archives of General Psychiatry 44(10):907–912, 1987PubMedCrossRef Waddington JL, Youssef HA, Dolphin C, et al.: Cognitive dysfunction, negative symptoms and tardive dyskinesia in schizophrenia. Archives of General Psychiatry 44(10):907–912, 1987PubMedCrossRef
47.
go back to reference Liddle PF, Crow TJ.: Age disorientation in chronic schizophrenia is associated with global intellectual impairment. The British Journal of Psychiatry 144:193–199, 1984PubMedCrossRef Liddle PF, Crow TJ.: Age disorientation in chronic schizophrenia is associated with global intellectual impairment. The British Journal of Psychiatry 144:193–199, 1984PubMedCrossRef
48.
go back to reference Spohn HE, Strauss ME: Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia. Journal of Abnormal Psychology 98(4):367–380, 1989PubMedCrossRef Spohn HE, Strauss ME: Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia. Journal of Abnormal Psychology 98(4):367–380, 1989PubMedCrossRef
49.
go back to reference Goldberg TE, Weinberger DR: Effects of neuroleptic medications on the cognition of patients with schizophrenia: A review of recent studies. Journal of Clinical Psychiatry 57(Suppl 9):62–65, 1996PubMed Goldberg TE, Weinberger DR: Effects of neuroleptic medications on the cognition of patients with schizophrenia: A review of recent studies. Journal of Clinical Psychiatry 57(Suppl 9):62–65, 1996PubMed
50.
go back to reference Galderisi S, Davidson M, Kahn RS, et al.: Correlates of cognitive impairment in first episode schizophrenia: The EUFEST study. Schizophrenia Research, 2009 Galderisi S, Davidson M, Kahn RS, et al.: Correlates of cognitive impairment in first episode schizophrenia: The EUFEST study. Schizophrenia Research, 2009
51.
go back to reference Chen EY, Lam LC, Chen RY, et al.: Negative symptoms, neurological signs and neuropsychological impairments in 204 Hong Kong Chinese patients with schizophrenia. The British Journal of Psychiatry 168:227–233, 1996PubMedCrossRef Chen EY, Lam LC, Chen RY, et al.: Negative symptoms, neurological signs and neuropsychological impairments in 204 Hong Kong Chinese patients with schizophrenia. The British Journal of Psychiatry 168:227–233, 1996PubMedCrossRef
52.
go back to reference Norman RM, Malla AK, Morrison-Stewart SL, et al.: Neuropsychological correlates of syndromes in schizophrenia. The British Journal of Psychiatry 170:134–139, 1997PubMedCrossRef Norman RM, Malla AK, Morrison-Stewart SL, et al.: Neuropsychological correlates of syndromes in schizophrenia. The British Journal of Psychiatry 170:134–139, 1997PubMedCrossRef
Metadata
Title
Is There Evidence for Late Cognitive Decline in Chronic Schizophrenia?
Authors
Jharna N. Shah
Salah U. Qureshi
Ali Jawaid
Paul E. Schulz
Publication date
01-06-2012
Publisher
Springer US
Published in
Psychiatric Quarterly / Issue 2/2012
Print ISSN: 0033-2720
Electronic ISSN: 1573-6709
DOI
https://doi.org/10.1007/s11126-011-9189-8

Other articles of this Issue 2/2012

Psychiatric Quarterly 2/2012 Go to the issue